Company: APXIF
Filing Date: 2025-06-13
Form Type: F-4/A
Source: 0001213900-25-054324
Chunk: 362

Company: APx Acquisition Corp. I
Filing Date: 2025-06-13
Form: F-4/A
Chunk 362
---
 oncology to prenatal care and rare diseases, and provide precise insights that allow physicians, patients, and their families to become aware of the impact that their genes have on their conditions and how these may affect them in the future. Heritas Argentina primarily derives revenue from its diagnostics division which provides clinical genetic tests relating to the fields of oncology, prenatal care, rare diseases and human microbiome, as well as other genetic sequencing services. On April 14, 2021, the shareholders of Heritas Argentina (i.e. Bioceres SA, CIBIC, Fabian Fay and Martin Vazquez) transferred their interest in Heritas Argentina to the Parent, resulting in the Parent becoming the direct and sole shareholder of Heritas Argentina. In 2022, after several years providing clinical genetic diagnostic tests in Argentina and expanding these services into Paraguay, Heritas Argentina diversified its product portfolio by launching a new business division. Rewell, initially launched as a direct -to -consumerbrand, was developed after the COVID -19pandemic, which significantly changed consumer habits by making at -hometesting a routine and making prevention and wellness more relevant to the broader population. Rewell builds on the advances in genetic and gut health testing technology and was designed for general consumers, who seek unique and personalized information to work on their long -termhealth by achieving an optimal lifestyle. Rewell starts with an at -homeDNA and microbiome test kit, and once samples are processed, consumers can view unique insights on their genetic health risks, physical performance, rest and stress, ancestry, nutrition and immunity, and personal traits. These results can be viewed on Rewell’s secure digital platform, where consumers could also, during the pilot phase, schedule a telemedicine consultation with a healthcare professional to interpret their results, and receive a health plan with recommendations to target the prevention of certain health issues and achieve health objectives. 179 On January 9, 2024, OmnigenicsAI was incorporated in the Cayman Islands. On February 26, 2024, the Parent entered into a contribution agreement with OmnigenicsAI, pursuant to which Parent contributed to OmnigenicsAI all of the issued and outstanding shares in Heritas Argentina, making Heritas Argentina a wholly owned subsidiary of OmnigenicsAI. OmnigenicsAI issued 30,000,000 Company Shares to Parent in connection with the Heritas Argentina contribution. In 2025, after selling Rewell for two and a half years through a direct -to-consumer(“